Fludarabine and once-daily intravenous busulfan for allogeneic bone marrow transplantation for Chediak-Higashi syndrome

Nancy Gordon, Craig A. Mullen, Hai Tran, Laura Worth, David Gomez Almaguer, Ka Wah Chan

Resultado de la investigación: Contribución a una revistaArtículo

12 Citas (Scopus)

Resumen

An HLA-identical sibling bone marrow transplant was done for a patient with Chediak-Higashi syndrome. The preparative regimen included intravenous fludarabine (40 mg/m2/d × 4) and busulfan (130 mg/m 2/d × 4). Busulfan was given once daily. Pharmacokinetic studies showed the area under the concentration-time curve of the once-daily intravenous busulfan was similar to that seen with the total daily dose administered with an every-6-hourly regimen. Toxicity was minimal. Myeloid engraftment occurred on day +17 and donor chimerism was complete. Fludarabine and once-daily intravenous busulfan is well tolerated and is adequate for engraftment of sibling transplant in Chediak-Higashi syndrome.

Idioma originalInglés
Páginas (desde-hasta)824-826
Número de páginas3
PublicaciónJournal of Pediatric Hematology/Oncology
Volumen25
N.º10
DOI
EstadoPublicada - 1 oct 2003

Huella dactilar

Chediak-Higashi Syndrome
Busulfan
Homologous Transplantation
Bone Marrow Transplantation
Siblings
Transplants
Chimerism
Pharmacokinetics
Bone Marrow
Tissue Donors
fludarabine

Citar esto

Gordon, Nancy ; Mullen, Craig A. ; Tran, Hai ; Worth, Laura ; Gomez Almaguer, David ; Chan, Ka Wah. / Fludarabine and once-daily intravenous busulfan for allogeneic bone marrow transplantation for Chediak-Higashi syndrome. En: Journal of Pediatric Hematology/Oncology. 2003 ; Vol. 25, N.º 10. pp. 824-826.
@article{5b61f918dc02456482ae3995a458199e,
title = "Fludarabine and once-daily intravenous busulfan for allogeneic bone marrow transplantation for Chediak-Higashi syndrome",
abstract = "An HLA-identical sibling bone marrow transplant was done for a patient with Chediak-Higashi syndrome. The preparative regimen included intravenous fludarabine (40 mg/m2/d × 4) and busulfan (130 mg/m 2/d × 4). Busulfan was given once daily. Pharmacokinetic studies showed the area under the concentration-time curve of the once-daily intravenous busulfan was similar to that seen with the total daily dose administered with an every-6-hourly regimen. Toxicity was minimal. Myeloid engraftment occurred on day +17 and donor chimerism was complete. Fludarabine and once-daily intravenous busulfan is well tolerated and is adequate for engraftment of sibling transplant in Chediak-Higashi syndrome.",
keywords = "Bone marrow transplantation, Chediak-Higashi syndrome, Fludarabine, Intravenous busulfan, Preparative regimen",
author = "Nancy Gordon and Mullen, {Craig A.} and Hai Tran and Laura Worth and {Gomez Almaguer}, David and Chan, {Ka Wah}",
year = "2003",
month = "10",
day = "1",
doi = "10.1097/00043426-200310000-00019",
language = "Ingl{\'e}s",
volume = "25",
pages = "824--826",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "10",

}

Fludarabine and once-daily intravenous busulfan for allogeneic bone marrow transplantation for Chediak-Higashi syndrome. / Gordon, Nancy; Mullen, Craig A.; Tran, Hai; Worth, Laura; Gomez Almaguer, David; Chan, Ka Wah.

En: Journal of Pediatric Hematology/Oncology, Vol. 25, N.º 10, 01.10.2003, p. 824-826.

Resultado de la investigación: Contribución a una revistaArtículo

TY - JOUR

T1 - Fludarabine and once-daily intravenous busulfan for allogeneic bone marrow transplantation for Chediak-Higashi syndrome

AU - Gordon, Nancy

AU - Mullen, Craig A.

AU - Tran, Hai

AU - Worth, Laura

AU - Gomez Almaguer, David

AU - Chan, Ka Wah

PY - 2003/10/1

Y1 - 2003/10/1

N2 - An HLA-identical sibling bone marrow transplant was done for a patient with Chediak-Higashi syndrome. The preparative regimen included intravenous fludarabine (40 mg/m2/d × 4) and busulfan (130 mg/m 2/d × 4). Busulfan was given once daily. Pharmacokinetic studies showed the area under the concentration-time curve of the once-daily intravenous busulfan was similar to that seen with the total daily dose administered with an every-6-hourly regimen. Toxicity was minimal. Myeloid engraftment occurred on day +17 and donor chimerism was complete. Fludarabine and once-daily intravenous busulfan is well tolerated and is adequate for engraftment of sibling transplant in Chediak-Higashi syndrome.

AB - An HLA-identical sibling bone marrow transplant was done for a patient with Chediak-Higashi syndrome. The preparative regimen included intravenous fludarabine (40 mg/m2/d × 4) and busulfan (130 mg/m 2/d × 4). Busulfan was given once daily. Pharmacokinetic studies showed the area under the concentration-time curve of the once-daily intravenous busulfan was similar to that seen with the total daily dose administered with an every-6-hourly regimen. Toxicity was minimal. Myeloid engraftment occurred on day +17 and donor chimerism was complete. Fludarabine and once-daily intravenous busulfan is well tolerated and is adequate for engraftment of sibling transplant in Chediak-Higashi syndrome.

KW - Bone marrow transplantation

KW - Chediak-Higashi syndrome

KW - Fludarabine

KW - Intravenous busulfan

KW - Preparative regimen

UR - http://www.scopus.com/inward/record.url?scp=0141889034&partnerID=8YFLogxK

U2 - 10.1097/00043426-200310000-00019

DO - 10.1097/00043426-200310000-00019

M3 - Artículo

C2 - 14528111

AN - SCOPUS:0141889034

VL - 25

SP - 824

EP - 826

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 10

ER -